4575
CanBas Co.,Ltd.
キャンバス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Jun 2021
108,945
Jun 2022
-
Jun 2023
-
Jun 2024
-
Jun 2025
-
Operating profit(thousand JPY)
Jun 2021
-547,671
Jun 2022
-846,438
Jun 2023
-965,965
Jun 2024
-1,262,041
Jun 2025
-1,109,563
Operating profit margin(%)
Jun 2021
-502.7
Jun 2022
-
Jun 2023
-
Jun 2024
-
Jun 2025
-
Profit before tax(thousand JPY)
Jun 2021
-529,784
Jun 2022
-854,327
Jun 2023
-1,242,858
Jun 2024
-1,208,349
Jun 2025
-1,156,668
Profit(thousand JPY)
Jun 2021
-531,034
Jun 2022
-855,577
Jun 2023
-1,244,108
Jun 2024
-1,209,599
Jun 2025
-1,157,918
Total assets(thousand JPY)
Jun 2021
1,295,610
Jun 2022
790,709
Jun 2023
2,085,999
Jun 2024
2,432,855
Jun 2025
3,050,766
Cash and cash equivalents(thousand JPY)
Jun 2021
1,154,754
Jun 2022
737,775
Jun 2023
1,617,795
Jun 2024
1,888,200
Jun 2025
2,827,879
Cash flows from operating activities(thousand JPY)
Jun 2021
-688,572
Jun 2022
-719,814
Jun 2023
-1,398,936
Jun 2024
-1,280,192
Jun 2025
-771,454
Cash flows from investing activities(thousand JPY)
Jun 2021
-
Jun 2022
182
Jun 2023
-
Jun 2024
-
Jun 2025
122
Cash flows from financing activities(thousand JPY)
Jun 2021
728,800
Jun 2022
282,751
Jun 2023
2,272,621
Jun 2024
1,538,270
Jun 2025
1,748,929
Return on equity(-)
Jun 2021
-
Jun 2022
-
Jun 2023
-
Jun 2024
-
Jun 2025
-
Equity ratio(%)
Jun 2021
27.2
Jun 2022
20.2
Jun 2023
91
Jun 2024
94.7
Jun 2025
95.4
Earnings per share(JPY per share)
Jun 2021
-70.01
Jun 2022
-88.31
Jun 2023
-83.03
Jun 2024
-67.9
Jun 2025
-61.14
Net assets per share(JPY per share)
Jun 2021
40.35
Jun 2022
13.85
Jun 2023
115.77
Jun 2024
127.87
Jun 2025
147.76
Dividend per share(-)
Jun 2021
-
Jun 2022
-
Jun 2023
-
Jun 2024
-
Jun 2025
-
Payout ratio(-)
Jun 2021
-
Jun 2022
-
Jun 2023
-
Jun 2024
-
Jun 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.